Skip to main
XNCR

Xencor (XNCR) Stock Forecast & Price Target

Xencor (XNCR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Xencor is poised for growth in the coming years with several promising pipeline products, including XmAb819 and XmAb541, which have demonstrated strong response rates in heavily pretreated ccRCC and ovarian cancer patients, respectively. The recent 2Q26 earnings report, which showed solid progress and updates on their key pipeline programs, is a positive indication of the company's potential. With a diverse revenue stream and strategic collaborations and partnerships, Xencor has a strong financial standing to support its research and development efforts for these novel antibody therapeutics.

Bears say

Xencor is showing positive signs with its strong 2Q26 EPS of $(0.29), ahead of analyst expectations of $(0.83), due to increased Ultomiris royalty revenue and a milestone payment from Zenas. The company's increased YE26 cash guidance of $420-440MM and reiterated runway through 2028 are also promising, with support from the recent settlement and milestone payments. Overall, Xencor has a promising pipeline with multiple upcoming catalysts, making it a company to watch in the biopharmaceutical industry.

Xencor (XNCR) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xencor (XNCR) Forecast

Analysts have given Xencor (XNCR) a Buy based on their latest research and market trends.

According to 8 analysts, Xencor (XNCR) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xencor (XNCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.